In Phase A, participants will get different doses and schedules of oral ABBV-744 tablet to establish safe dosing regimen. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://elizabetha444uhv9.blogolenta.com/profile